Revolution Medicines said on May 1 that the U.S. Food and Drug Administration issued a safe to proceed letter allowing the company to begin an expanded access treatment protocol for daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The move opens a monitored and controlled path for some patients with the cancer to receive the investigational drug outside a trial.
The letter is a crucial step toward opening an expanded access program for daraxonrasib, an investigational RAS(ON) inhibitor developed by the clinical-stage precision oncology company. Revolution Medicines said it is moving as quickly as possible to ensure safe and equitable access for eligible patients in the United States, but it also said it cannot accept direct requests from patients or caregivers. Under the process, all requests must start with a licensed treating physician.
Expanded access programs are designed for investigational medicines when patients have limited options, and they are tightly managed under FDA regulations. In this case, the company said the protocol is meant to offer treatment access in a monitored and controlled setting, which is the key condition that allowed the agency to clear the next step. For families facing metastatic pancreatic ductal adenocarcinoma after prior treatment, the announcement turns a regulatory letter into something more immediate: a possible route to a drug that had previously been out of reach.
That path is still narrow. Revolution Medicines did not say how many patients may qualify or when the first treatments could begin, and the company’s own instructions make clear that access is not handled by a patient hotline or email inbox. The practical gatekeeper is the physician, not the family, and that is likely to shape how quickly any eligible patient can move forward.
For now, the company has answered the central question behind the announcement. The FDA has allowed the expanded access protocol to start, and Revolution Medicines says it will push to make that access available as fast as it can while keeping the process controlled.
